Company: SHPH
Filing Date: 2025-02-26
Form Type: 10-K
Source: 0001493152-25-008300
Chunk: 430

Company: Shuttle Pharmaceuticals Holdings, Inc.
Filing Date: 2025-02-26
Form: 10-K
Item: Item 1B
Chunk 430
---
 Company did not consult with the New Accountant regarding
either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit
opinion that might be rendered on the Company’s financial statements; or (ii) any matter that was the subject of a “disagreement”
or a “reportable event” (as those terms are defined in Item 304(a)(1)(iv) and (a)(1)(v) of Regulation S-K, respectively).

67

On
March 21, 2023, the Company provided the Former Accountant with the disclosures contained in the Form 8-K disclosing the dismissal of
the Former Accountant and requested in writing that the Former Accountant furnish the Company with a letter addressed to the SEC stating
whether or not they agree with such disclosures. The Former Accountant’s response was filed as Exhibit 16.1 to the Original Form
8-K.

On
May 3, 2024, the SEC entered a cease-and-desist order against our Former Accountant, which resulted in the Re-audit of our financial
statements for the year ended December 31, 2022, which had been audited by our Former Accountant. Since that time and as a result of
the Re-audit, as of July 10, 2024, the Company and the audit committee of our board of directors, in consultation with our current auditor,
Forvis Mazars LLP, concluded that our audited financial statements for the year ended December 31, 2022, our audited financial statements
for the year ended December 31, 2023 and the quarterly periods included in the Company’s 2023 Form 10-K, and the Quarterly Report
on Form 10-Q for the period ended March 31, 2024, required restatement and were not reliable. We reported this determination in our Form
8-K filed on July 16, 2024 and subsequently filed an Annual Report on Form 10-K/A amending the Company’s 2023 Form 10-K and a Quarterly
Report on form 10-Q/A amending the Company’s Form 10-Q for the period ended March 31, 2024, which reports were each filed on September
4, 2024.

Item
9A. Controls and Procedures

Evaluation
of Disclosure Controls and Procedures 

Disclosure
controls and procedures (as defined in Exchange Act Rule 15d-15(e))